The application of viral vectors to enhance regeneration after peripheral nerve repair

Neurological Research

Volumn 30, Issue 10, 2008, Pages 1039-1046

  Tannemaat, Martijn R ^a,b   Verhaagen, Joost ^a   Malessy, Martijn ^b  

^a NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Nerve regeneration; Nerve repair; Peripheral nerve; Viral vectors

Indexed keywords

ADENOVIRUS VECTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; DNA; DOXYCYCLINE; FIBROBLAST GROWTH FACTOR 2; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HERPES SIMPLEX VIRUS VECTOR; LENTIVIRUS VECTOR; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; NEUROTROPHIN 3; NEUROTROPHIN 4; PARVOVIRUS VECTOR; RECOMBINANT NERVE GROWTH FACTOR; RETROVIRUS VECTOR; TETRACYCLINE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ALZHEIMER DISEASE; DIABETIC NEUROPATHY; DNA MODIFICATION; DRUG HALF LIFE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HUMAN; INJECTION SITE PAIN; INJECTION SITE REACTION; NERVE FIBER TRANSECTION; NERVE GRAFT; NERVE REGENERATION; PARKINSON DISEASE; PERIPHERAL NERVE; PERIPHERAL NERVE INJURY; REVIEW; SCHWANN CELL; SCIATIC NEUROPATHY; SURAL NERVE; TRANSGENE;

ANIMALS; GENE THERAPY; GENETIC VECTORS; HUMANS; LENTIVIRUS; NERVE REGENERATION; PERIPHERAL NERVOUS SYSTEM DISEASES; TRANSDUCTION, GENETIC;

EID: 57449089045     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/174313208X362514     Document Type: Review

References (58)

1. Apfel SC. Is the therapeutic application of neurotrophic factors dead? Ann Neurol 2002; 51: 8-11
2. Apfel SC, Schwartz S, Adornato BT, et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group. JAMA 2000; 284: 2215-2221
3. Araki K, Shiotani A, Watabe K, et al. Adenoviral GDNF gene transfer enhances neurofunctional recovery after recurrent laryngeal nerve injury. Gene Ther 2006; 13: 296-303
4. Azzouz M, Ralph GS, Storkebaum E, et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004; 429: 413-417
5. Barati S, Hurtado PR, Zhang SH, et al. GDNF gene delivery via the p75(NTR) receptor rescues injured motor neurons. Exp Neurol 2006; 202: 179-188
6. Blesch A, Conner J, Pfeifer A, et al. Regulated lentiviral NGF gene transfer controls rescue of medial septal cholinergic neurons. Mol Ther 2005; 11: 916-925
7. Blesch A, Tuszynski MH. Spontaneous and neurotrophin-induced axonal plasticity after spinal cord injury. Prog Brain Res 2002; 137: 415-423
8. Blesch A, Tuszynski MH. Transient growth factor delivery sustains regenerated axons after spinal cord injury. J Neurosci 2007; 27: 10535-10545
9. Blits B, Carlstedt TP, Ruitenberg MJ, et al. Rescue and sprouting of motoneurons following ventral root avulsion and reimplantation combined with intraspinal adeno-associated viral vector-mediated expression of glial cell line-derived neurotrophic factor or brain-derived neurotrophic factor. Exp Neurol 2004; 189: 303-316
10. Bosse F, Hasenpusch-Theil K, Kury P, et al. Gene expression profiling reveals that peripheral nerve regeneration is a consequence of both novel injury-dependent and reactivated developmental processes. J Neurochem 2006; 96: 1441-1457
11. Boyd JG, Gordon T. A dose-dependent facilitation and inhibition of peripheral nerve regeneration by brain-derived neurotrophic factor. Eur J Neurosci 2002; 15: 613-626
12. Boyd JG, Gordon T. Glial cell line-derived neurotrophic factor and brain-derived neurotrophic factor sustain the axonal regeneration of chronically axotomized motoneurons in vivo. Exp Neurol 2003; 183: 610-619
13. Boyd JG, Gordon T. Neurotrophic factors and their receptors in axonal regeneration and functional recovery after peripheral nerve injury. Mol Neurobiol 2003; 27: 277-324
14. de Ruiter GC, Malessy MJ, Alaid AO, et al. Misdirection of regenerating motor axons after nerve injury and repair in the rat sciatic nerve model. Exp Neurol 2008; 211: 339-350
15. Dijkhuizen PA, Pasterkamp RJ, Hermens WT, et al. Adenoviral vector-mediated gene delivery to injured rat peripheral nerve. J Neurotrauma 1998; 15: 387-397
16. Dittrich F, Ochs G, Grosse-Wilde A, et al. Pharmacokinetics of intrathecally applied BDNF and effects on spinal motoneurons. Exp Neurol 1996; 141: 225-239
17. Eriksdotter Jonhagen M, Nordberg A, Amberla K, et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord 1998; 9: 246-257
18. Geller AI, Keyomarsi K, Bryan J, et al. An efficient deletion mutant packaging system for defective herpes simplex virus vectors: Potential applications to human gene therapy and neuronal physiology. Proc Natl Acad Sci USA 1990; 87: 8950-8954
19. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992; 89: 5547-5551
20. Gramsbergen A, Ijkema-Paassen J, Meek MF. Sciatic nerve transection in the adult rat: Abnormal EMG patterns during locomotion by aberrant innervation of hindleg muscles. Exp Neurol 2000; 161: 183-193
21. Gravvanis AI, Lavdas A, Papalois AE, et al. Effect of genetically modified Schwann cells with increased motility in end-to-side nerve grafting. Microsurgery 2005; 25: 423-432
22. Haastert K, Lipokatic E, Fischer M, et al. Differentially promoted peripheral nerve regeneration by grafted Schwann cells overexpressing different FGF-2 isoforms. Neurobiol Dis 2006; 21: 138-153
23. Hendriks WT, Eggers R, Carlstedt TP, et al. Lentiviral vector-mediated reporter gene expression in avulsed spinal ventral root is short-term, but is prolonged using an immune "stealth" transgene. Restor Neurol Neurosci 2007; 25: 585-599
24. Hendriks WT, Ruitenberg MJ, Blits B, et al. Viral vector-mediated gene transfer of neurotrophins to promote regeneration of the injured spinal cord. Prog Brain Res 2004; 146: 451-476
25. Ho DY, Mocarski ES. Herpes simplex virus latent RNA (LAT) is not required for latent infection in the mouse. Proc Natl Acad Sci USA 1989; 86: 7596-7600
26. Hoke A. Mechanisms of disease: What factors limit the success of peripheral nerve regeneration in humans? Nat Clin Pract Neurol 2006; 2: 448-454
27. Hoke A, Redett R, Hameed H, et al. Schwann cells express motor and sensory phenotypes that regulate axon regeneration. J Neurosci 2006; 26: 9646-9655
28. Jakobsson J, Ericson C, Rosenqvist N, et al. Lentiviral vectors. Int Rev Neurobiol 2003; 55: 111-122
29. Jimenez CR, Stam FJ, Li KW, et al. Proteomics of the injured rat sciatic nerve reveals protein expression dynamics during regeneration. Mol Cell Proteomics 2005; 4: 120-132
30. Jubran M, Widenfalk J. Repair of peripheral nerve transections with fibrin sealant containing neurotrophic factors. Exp Neurol 2003; 181: 204-212
31. Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: An open label, phase I trial. Lancet 2007; 369: 2097-2105
32. Kaspar BK, Llado J, Sherkat N, et al. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 2003; 301: 839-842
33. Kemp SW, Walsh SK, Zochodne DW, et al. A novel method for establishing daily in vivo concentration gradients of soluble nerve growth factor (NGF). J Neurosci Methods 2007; 165: 83-88
34. Li Q, Ping P, Jiang H, et al. Nerve conduit filled with GDNF gene-modified Schwann cells enhances regeneration of the peripheral nerve. Microsurgery 2006; 26: 116-121
35. Lundborg G. A 25-year perspective of peripheral nerve surgery: Evolving neuroscientific concepts and clinical significance. J Hand Surg [Am] 2000; 25: 391-414
36. Maggi SP, Lowe JB 3rd, Mackinnon SE. Pathophysiology of nerve injury. Clin Plast Surg 2003; 30: 109-126
37. Mann R, Mulligan RC, Baltimore D. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 1983; 33: 153-159
38. Mazarakis ND, Azzouz M, Rohll JB, et al. Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum Mol Genet 2001; 10: 2109-2121
39. Moore K, MacSween M, Shoichet M. Immobilized concentration gradients of neurotrophic factors guide neurite outgrowth of primary neurons in macroporous scaffolds. Tissue Eng 2006; 12: 267-278
40. Moro K, Shiotani A, Watabe K, et al. Adenoviral gene transfer of BDNF and GDNF synergistically prevent motoneuron loss in the nucleus ambiguus. Brain Res 2006; 1076: 1-8
41. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267
42. Nguyen QT, Sanes JR, Lichtman JW. Pre-existing pathways promote precise projection patterns. Nat Neurosci 2002; 5: 861-867
43. Perez MC, Hunt SP, Coffin RS, et al. Comparative analysis of genomic HSV vectors for gene delivery to motor neurons following peripheral inoculation in vivo. Gene Ther 2004; 11: 1023-1032
44. Pezet S, McMahon SB. Neurotrophins: Mediators and modulators of pain. Annu Rev Neurosci 2006; 29: 507-538
45. Sakamoto T, Kawazoe Y, Shen JS, et al. Adenoviral gene transfer of GDNF, BDNF and TGF beta 2, but not CNTF, cardiotrophin-1 or IGF1, protects injured adult motoneurons after facial nerve avulsion. J Neurosci Res 2003; 72: 54-64
46. Senn C, Fraefel C, Breakefield XO. HSV amplicon vectors for gene delivery to the nervous system. In: Kaplitt MG, During MJ, eds. Gene Therapy in the Central Nervous System, Boston, MA: Academic Press, 2006: pp. 25-38
47. Stam FJ, MacGillavry HD, Armstrong NJ, et al. Identification of candidate transcriptional modulators involved in successful regeneration after nerve injury. Eur J Neurosci 2007; 25: 3629-3637
48. Sunderland S. Nerve Injuries and Their Repair: A Critical Appraisal, Melbourne: Chuchill Livingstone, 1991
49. Tannemaat MR, Boer GJ, Verhaagen J, et al. Genetic modification of human sural nerve segments by a lentiviral vector encoding nerve growth factor. Neurosurgery 2007; 61: 1286-1294
50. Taylor L, Jones L, Tuszynski MH, et al. Neurotrophin-3 gradients established by lentiviral gene delivery promote short-distance axonal bridging beyond cellular grafts in the injured spinal cord. J Neurosci 2006; 26: 9713-9721
51. Timmer M, Robben S, Muller-Ostermeyer F, et al. Axonal regeneration across long gaps in silicone chambers filled with Schwann cells overexpressing high molecular weight FGF-2. Cell Transplant 2003; 12: 265-277
52. Tria MA, Fusco M, Vantini G, et al. Pharmacokinetics of nerve growth factor (NGF) following different routes of administration to adult rats. Exp Neurol 1994; 127: 178-183
53. Tuszynski MH, Thal L, Pay M, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005; 11: 551-555
54. Watanabe TS, Ohtori S, Koda M, et al. Adenoviral gene transfer in the peripheral nervous system. J Orthop Sci 2006; 11: 64-69
55. Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: Vector toolkit for human gene therapy. Mol Ther 2006; 14: 316-327
56. Xu Y, Gu Y, Wu P, et al. Efficiencies of transgene expression in nociceptive neurons through different routes of delivery of adeno-associated viral vectors. Hum Gene Ther 2003; 14: 897-906
57. Yin Q, Kemp GJ, Yu LG, et al. Neurotrophin-4 delivered by fibrin glue promotes peripheral nerve regeneration. Muscle Nerve 2001; 24: 345-351
58. Young C, Miller E, Nicklous DM, et al. Nerve growth factor and neurotrophin-3 affect functional recovery following peripheral nerve injury differently. Restor Neurol Neurosci 2001; 18: 167-175